Eli Lilly said retatrutide delivered stronger results than Ozempic 2 mg in an 80-week Phase 3 TRANSCEND-T2D-2 study involving 1,298 adults with type 2 diabetes.
In the trial, participants taking the 9 mg dose of retatrutide lost an average of 44.3 pounds, while those on the 12 mg dose lost 47.4 pounds. By comparison, the Ozempic group averaged 20.9 pounds of weight loss.
Retatrutide also led to larger average reductions in A1C, with a drop of 2.2 percentage points versus 1.8 points for Ozempic.
The treatment showed greater gains than Ozempic in cholesterol, triglycerides, and systolic blood pressure as well.
Gastrointestinal side effects were the most frequently reported, and more patients stopped treatment on retatrutide, particularly at the 12 mg dose.
Retatrutide has not yet been approved by the FDA. Lilly said it plans to pursue approval in early 2027.
More from Digilifetrends
Once-weekly IcoSema lowers weight and systolic blood pressure in type 2 diabetes
A once-weekly injection that combines a long-acting basal insulin with semaglutide was linked to meaningful reductions in body weight, lower systolic blood pressure and better…
7 min read · Updated 2026-10-28Lilly’s experimental weight-loss drug outperforms Ozempic in study
(TNND) — Eli Lilly says a late-stage study indicates its experimental once-weekly injection retatrutide may help adults with Type 2 diabetes shed more weight than Ozempic, while…
3 min read · Updated 2026-10-28Lilly’s Experimental Drug Outperforms Ozempic in Weight-Loss Trial
A late-stage study indicates that Eli Lilly’s experimental weekly injection retatrutide may lead to greater weight loss than Ozempic in adults with Type 2 diabetes, while also…
3 min read · Updated 2026-10-28